Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...

A recent study by researchers from the University of California San Diego and collaborators has uncovered a new molecular ...

Limitations to the study included a lack of serum urate measurements and the potential for residual confounding; people's ...

Among patients with gout in the US, Black individuals and those living in the South were associated with reduced adherence to allopurinol.

Radiographic scoring of articular damage is useful for evaluating disease progression and response to treatment in patients with rheumatic diseases; currently, however, there is no validated ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...